VIRAL VECTOR AND PLASMID DNA TESTING SERVICES MARKET ANALYSIS
Global Viral Vector and Plasmid DNA Testing Services Market- Key Developments
In January 2022, Sarepta Therapeutics, Inc., a biotechnology company, and Aldevron, A corporate company, collaborated for the supply of GMP grade plasmid to meet the needs of Sarepta's gene therapy clinical trials and commercial supply.
In August 26, 2021, INOVIO, a biotechnology has announced that it has received regulatory authorization from Brazil's ANVISA (Agência Nacional de Vigilância Sanitária), the national health regulatory agency of Brazil, to initiate the global Phase 3 segment of its Phase 2/3 trial, INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy), for INO-4800, its DNA vaccine candidate for COVID-19. INOVIO plans to conduct the global INNOVATE Phase 3 segment in multiple countries, including Brazil, with partner Advaccine Biopharmaceuticals Suzhou Co., Ltd. (Advaccine).
In July 2021, Thermo Fisher Scientific, a pharmaceutical company, announced the opening of its new cGMP (Current good manufacturing practices) plasmid DNA manufacturing facility in Carlsbad California, U.S.
In June, 2020, Genprex, Inc., a clinical-stage gene therapy company, announced collaboration with Aldevron, a biotechnology company, in order to manufacture GMP plasmid DNA for Genprex's Oncoprex gene therapy portfolio.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowPress Release
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
